Lee Kyo Won, Cho Chan Woo, Lee Nuri, Choi Gyu-Seong, Cho Yang Hyun, Kim Jong Man, Kwon Choon Hyuck David, Joh Jae-Won
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Ann Surg Treat Res. 2017 Sep;93(3):152-158. doi: 10.4174/astr.2017.93.3.152. Epub 2017 Aug 30.
This study was designed to assess the outcome of the extracorporeal membrane oxygenation (ECMO) in liver transplantation (LT) recipients with refractory septic shock and predict the prognosis of those cases.
From February 2005 to October 2012, ECMO was used in 8 cases of refractory septic shock. Laboratory values including lactate and total bilirubin level just before starting ECMO were obtained and sepsis-related organ failure assessment (SOFA) score, acute physiology and chronic health evaluation (APACH) II score and simplified acute physiology score (SAPS) 3 were calculated. Subsequent peak serum lactate and total bilirubin level, and SOFA score after 24 hours of starting ECMO were measured.
Comparisons were made between survivors and nonsurvivors. ECMO was weaned off successfully in 3 patients (37.5%) and 2 patients (25%) survived to hospital discharge. Clinical scores including SOFA, APACH II, and SAPS3 and laboratory results including lactate, total bilirubin and CRP were not significantly different between survivor and nonsurvivor groups. Lactate level and SOFA score tended to decrease after ECMO support in survivor group and total bilirubin and CRP level tended to increase in nonsurvivor group.
Our findings suggest that the implantation of ECMO might be considered in highly selected LT recipients with refractory septic shock.
本研究旨在评估体外膜肺氧合(ECMO)在难治性感染性休克肝移植(LT)受者中的疗效,并预测这些病例的预后。
2005年2月至2012年10月,8例难治性感染性休克患者接受了ECMO治疗。记录开始ECMO治疗前的实验室指标,包括乳酸和总胆红素水平,并计算脓毒症相关器官功能衰竭评估(SOFA)评分、急性生理与慢性健康状况评估(APACHE)II评分和简化急性生理学评分(SAPS)3。测量开始ECMO治疗24小时后的血清乳酸峰值、总胆红素水平及SOFA评分。
比较存活者与非存活者。3例患者(37.5%)成功撤机,2例患者(25%)存活至出院。存活组与非存活组的临床评分(包括SOFA、APACHE II和SAPS3)及实验室检查结果(包括乳酸、总胆红素和CRP)无显著差异。存活组ECMO支持后乳酸水平和SOFA评分呈下降趋势,非存活组总胆红素和CRP水平呈上升趋势。
我们的研究结果表明,对于经过严格筛选的难治性感染性休克肝移植受者,可考虑植入ECMO。